Introduction
Nutritional support of extremely low-birth-weight (ELBW) infants has a critical role in the prevention, amelioration and recovery from bronchopulmonary dysplasia (BPD). Despite animal and human studies demonstrating the importance of providing adequate energy, protein and certain nutrients, no evidence-based nutritional guidelines exist. Infants with developing and established chronic lung disease therefore create a special challenge to neonatal clinicians. This article is a brief review of the general approach to meeting the nutritional needs of these infants and the attempts to find specific nutrients to prevent or ameliorate BPD.
Postnatal growth and BPD
Extrauterine growth restriction is a common problem in premature neonates, especially for those at the earliest gestational ages and those with serious morbidities. Clark et al. 1 reported on more than 24 000 premature infants born in 124 Pediatrix Medical Group sites from 1997 to 2000. More than half of infants less than 27 weeks gestation had weights less than the 10th percentile at the time of discharge from the NICU. Their retrospective database review showed that male gender, assisted ventilation on day 1 of life, need for respiratory support at 28 days of age, necrotizing enterocolitis (NEC) and postnatal exposure to corticosteroids were factors independently associated with extrauterine growth restriction.
Poor postnatal growth during the first weeks of life is associated with BPD as well as long-term problems of growth and neurodevelopment. A recent report from the National Institute of Child Health and Human Development (NICHD) Neonatal Network of ELBW infants born in 1994 to 1995 demonstrated that 56% of infants in the lowest growth quartile developed BPD, compared with 31% of infants in the highest growth quartile. Infants in the lowest quartile were also more likely to have had NEC, sepsis and received postnatal steroids, and there was a strong association between growth in the neonatal intensive care unit (NICU) and neurodevelopmental outcome at 18 to 22 months. 2 ELBW infants begin life with low-energy reserves. Accretion of expendable energy occurs late in gestation: the expendable nonprotein energy reserve at 28 weeks is less than 200 kcal/kg, with 2% of their body weight as fat and 0.5% as glycogen. In contrast, term infants are born with 1500 kcal/kg of expendable energy, with 15% of their body weight as fat and 1.2% as glycogen.
ELBW infants are often catabolic in the first hours to days of life owing to illness, high metabolic demands and feeding strategies. The traditional focus in the first few days of life was to maintain fluid balance and provide glucose as the only source of energy. Rat studies have shown that decreased energy intake for the first 21 days of life leads to adults with lower lung weight, reduced number of alveoli and low tissue stores of pulmonary surfactant. 3 In infants receiving fat-free intravenous nutrition, there is a correlation between glucose intake and CO 2 production. Maximum neonatal glucose oxidative capacity is 12 to 13 mg/kg per minute, or 18 g/kg per day. Providing of excessive intravenous glucose could potentially overwhelm the neonate's glucose oxidative capacity, resulting in increased oxygen consumption, energy expenditure and CO 2 production. Yunis and Oh 4 studied the effects of high glucose intakes on infants with BPD. At baseline, study infants with BPD had significantly higher basal oxygen consumption, resting energy expenditure and basal CO 2 production. When subjected to glucose infusions of 12 mg/kg per minute, these infants had a 21% rise in basal oxygen consumption, basal CO 2 production and resting energy expenditure (all P<0.05). 4 Despite these and other metabolic studies suggesting problems with excessive energy intake, there are no clinical studies of outcomes at different energy intakes. Provision of increased glucose has not been associated with respiratory failure, and high-fat formulas have not been demonstrated to significantly change partial pressure of CO 2 or respiratory outcomes.
It has recently become standard practice to administer amino acid-containing solutions beginning at birth. This has been shown to be beneficial to ELBW neonates in a number of ways: (1) they can be in positive nitrogen balance from the first day of life, (2) they can maintain nearly normal amino-acid profiles, (3) they can tolerate higher energy intakes with less hyperglycemia, and (4) they will have improved growth through the initial hospitalization, with fewer being less than the 10th percentile at discharge.
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Silver bullets Are there specific nutritional factors that can prevent or ameliorate BPD? Attempts to improve outcomes with nutritional supplements have largely been unsuccessful. These have included nutrients to enhance protection from oxidative lung injury (vitamin E, selenium, N-acetyl cysteine, superoxide dismutase), to improve surfactant function (inositol) and to improve pulmonary cell growth and differentiation (vitamin A). The only therapy with proven, although modest, benefit to date is vitamin A.
Vitamin A Animals with vitamin A deficiency develop necrotizing tracheobronchitis that is histologically very similar to BPD. Small studies of vitamin A supplementation reported before 1997 were inconclusive, in part owing to large variations in the BPD rates of the control populations. The NICHD Neonatal Research Network trial published in 1999 included 807 infants who received 5000 IU of vitamin A intramuscularly three times per week for 4 weeks. Oxygen requirement at 36-week postmenstrual age was modestly decreased in the vitamin A group, with no differences in home oxygen use, bronchodilator therapy or respiratory rehospitalizations.
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Vitamin E Vitamin E is an antioxidant that scavenges excessive oxygen radicals. The largest clinical trial published to date (n ¼ 268) was performed in the presurfactant era. Very-low-birth weight (VLBW) infants were randomized to receive oral vitamin E, 25 U daily or placebo for 6 weeks. Serum vitamin E levels were well above normal adult levels by the end of the first week. BPD was defined as 'cystic or fibrotic changes on chest roentgenograms.' There were no differences in early death, mortality from BPD, BPD at 28 days, sepsis or NEC. 13 Selenium Selenium (Se) is a required constituent of the endogenous antioxidant glutathione peroxidase. In experimental animals, Se deficiency is associated with increased susceptibility to oxidative lung injury, and low-serum Se concentrations at 28 days of age were associated with poor respiratory outcomes in VLBW infants. A randomized placebo-controlled trial of Se supplementation was performed on 534 VLBW infants in New Zealand. Se was administered from week 1 of life until 36 weeks post menstrual age (PMA), dosed at 7 mcg/kg per day if parenteral and 5 mcg/kg per day if oral. There were no differences in oxygen requirements at 28 days postnatal age or 36 weeks PMA. Although there was no link between Se levels during the study and outcome, lower pre-randomization Se levels were associated with worse outcomes. 14 
Superoxide dismutase
Superoxide dismutases catalyze the conversion of superoxide anions to hydrogen peroxide and oxygen. A multicenter randomized, double blind, placebo-controlled study of 302 infants born in 1997 to 1998 with birth weights less than 1200 g was performed in 15 NICUs in the United States. Infants were enrolled at less than 24 hour of age if they were on the ventilator and had received surfactant therapy. Treated infants received recombinant human superoxide dismutase (r-h CuZnSOD), 5 mg/kg in 2 ml saline, intratracheally in two divided doses. Additional doses were given every 48 h until 28 days of age as long the infant remained on the ventilator. The incidence of BPD at 28 days, defined by chest X-ray findings and need for supplemental oxygen, varied widely between centers, ranging from 10 to 61%. Despite using an 'optimized regression model' that included the hospital of enrollment, there were no differences in BPD at 28 days, BPD at 36 weeks PMA, number of days on oxygen or number of days in the hospital. Interestingly, infants in the treatment group who were less than 27 weeks gestation at enrollment had a significant reduction in the number of subsequent hospitalizations and the use of asthma medications. 15 
Inositol
Phospholipids that incorporate the six-carbon sugar inositol are important in cell membrane functions. Inositol is present in high concentrations in the sera of immature fetuses, and studies of the effects of inositol deprivation and supplementation suggest a critical role in fetal and early neonatal life. It is involved in the shift from the production of phosphatidylinositol-rich surfactant in the immature lung to the production of phosphatidylglycerol-rich surfactant in the mature lung. Inositol supplementation of neonates in the pre-surfactant era reduced the risk of BPD, but this finding did not hold up in later studies of neonates who received surfactant replacement therapy. However, despite no reduction in BPD, there were significant reductions in severe retinopathy of prematurity and severe intraventricular hemorrhage. The NICHD Neonatal Research Network is currently conducting a Phase II pharmacokinetic study comparing two different doses (60 and 120 mg/kg) of inositol administered intravenously, with enrollment scheduled to end in late 2006. Future studies examining clinical outcomes are planned. 16 Enriched formulas and supplements After infants with BPD move to the convalescent phase of their NICU stay, they continue to require extra energy and protein to grow at appropriate rates. Not only are clinicians challenged on how best to meet these needs in the hospital, but after discharge as well. A 1998 study by Brunton et al. 17 included 60 VLBW infants with BPD at 37 weeks PMA and compared two formulas that were specially manufactured for the study. Both formulas supplied 27 kcal/oz, but one had higher protein (2.5 versus 1.6 g per 100 kcal) and mineral (Ca, P, Zn, Mg, Na, K, Fe and Cu) content. The infants who received the supplemented formula for 3 months had higher net protein and mineral accretion, and increased lean body mass and bone mineral accretion. The effects were more pronounced in males.
Currently available specialized premature formulas (3.0 g per 100 kcal) and postdisharge formulas (2.8 g per 100 kcal) contain significantly more protein than that used by Brunton et al. A more recent study, conducted by Cooke et al., 18 in 18 healthy VLBW infants compared the effects of giving isocaloric formulas containing either 3.6 g of protein per 100 kcal versus the standard 3.0 g per 100 kcal. In both formulas, the protein was provided as fully hydrolyzed bovine whey protein. The high-protein group showed greater nitrogen balance and weight gain without any evidence of uremia or metabolic acidosis. The higher amount of protein used in this study is the upper limit recommended in 2002 by an Expert Panel convened by the Life Sciences Research Office of the American Society for Nutritional Sciences. 19 A relatively new challenge for neonatal care providers stems from the Center for Disease Control/American Diabetic Association (CDC/ADA) recommendation that formula powders be eliminated from the NICU owing to questionable sterility. Ross Products/Abbott Laboratories and Mead Johnson Nutritionals addressed this issue by sending letters to physicians recommending that concentrated liquid formulas be added to premature formulas when additional caloric density was required. Ross first recommended using PediaSure s , a 30 kcal/oz formula designed for infants over 1 year of age that contains 3.0 g protein per 100 kcal. There are limited data on using concentrated formula supplements in neonates. One study in 27 infants with BPD over 44 weeks corrected age compared PediaSure s to Enfamil s Premature LIPIL s with added Polycose (glucose polymers), Casec (casein powder) and corn oil. Both formulas supplied 30 kcal/oz. Both groups had similar growth and feeding tolerance, but the PediaSure s group had better serum albumin and blood urea nitrogen (BUN), likely owing to the higher protein content. 20 In early 2006, Ross/Abbott introduced Similac Special Care 30 as a liquid concentrated formula for use in the NICU; however, there are currently no published clinical studies.
Another dilemma is the breast-fed infant with BPD. Clinicians must consider the increased energy and protein needs of these infants while at the same time promote breast-feeding for longterm health and development. Using commercial human milk fortifiers in a ratio of four packs per 100 ml milk adds 1 g of protein and 4 kcal/oz. However, the energy and protein content of human milk varies widely and changes during the infant's first months of life, and most NICUs are not able to measure the protein or caloric content of mother's milk. Standard supplementation schemes with commercial human milk fortifiers may be inadequate to meet the infant's needs. Arslanoglu et al. 21 recently showed that individualizing the amount of fortification guided by twice-weekly BUN determinations can lead to improved gains in weight, length and head circumference. They adjusted the amount of fortification to keep the BUN between 9 and 14 g/dl. The first stage increase was an additional pack of human milk fortifier, whereas the second and third stages used 0.4 and 0.8 g, respectively, of bovine whey protein concentrate.
Lastly, feeding dysfunction may exacerbate growth problems in infants with BPD owing to both decreased nutrient intake and increased caloric expenditure. Gewolb and Vice 22 quantitatively assessed the coordination of respiration and swallow in infants with and without BPD at 32 to 40 weeks postmenstrual age. They found decreased rhythmic integration of respiration into feeding episodes and increased apneic swallow runs in infants with BPD. This confirms the common clinical observation of the need for more frequent 'breaks' and close monitoring when feeding these infants.
A novel approach to solving this problem is being developed at the University of Kansas by Barlow co-workers. 23, 24 They have studied the neurophysiology of the suck central pattern generator (CPG) in infants and developed a 'motorized pacifier' to deliver patterned orosensory events. Pilot studies in infants with dyscoordinated suck/swallow patterns suggest that this device can be used therapeutically to entrain the suck CPG and improve both nutritive and non-nutritive sucking patterns.
Conclusion
The nutritional support of ELBW infants plays a critical role in the prevention, amelioration and recovery from BPD. The use of nutrients to enhance protection from oxidative lung injury (vitamin E, selenium, N-acetyl cysteine, superoxide dismutase) has fallen short of expectations leaving much to be desired. However, the modest benefits derived from the use of vitamin A supplementation to improve pulmonary cell growth and differentiation are promising. Nutritional management providing adequate energy, protein and nutrients is imperative for proper postnatal growth and development, thus supporting further research to explore the possible benefits of nutrition in BPD.
